{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:12Z","timestamp":1772119572616,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platinum-based doublet chemotherapy is commonly used in the treatment of non-small cell lung cancer (NSCLC). A growing body of evidence indicates that incorporating antiangiogenic agents into platinum-based chemotherapy may enhance the survival outcomes for NSCLC patients. However, the optimal administration protocol for intravenous recombinant human endostatin (rh-endostatin), an antiangiogenic agent, remains uncertain at present.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to investigate the efficacy and safety of 5-d continuous intravenous infusion of rh-endostatin in combination with chemotherapy for patients with advanced NSCLC. The predictive biomarkers for this treatment regimen were further probed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single-arm multicenter study enrolled a total of 48 patients with advanced NSCLC who were histologically or cytologically confirmed but had not received any prior treatment from January 2021 to December 2022. Prior to the chemotherapy, these patients received a continuous intravenous infusion of rh-endostatin (210\u00a0mg) over a period of 120\u00a0h, using an infusion pump. The chemotherapy regimen included a combination of platinum with either pemetrexed or paclitaxel, given in 21-day cycles. The primary endpoint of the study was median progression-free survival (mPFS), and the secondary endpoints included median overall survival (mOS), objective response rate (ORR), disease control rate (DCR), and assessment of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mPFS was 6.5 months (95% confidence interval (CI): 3.8\u20139.1\u00a0m) while the mOS was 12.3 months (95% CI: 7.6\u201318.5\u00a0m). The ORR and DCR was 52.1% and 75.0%, respectively. Leukopenia (52.1%), anemia (33.3%), and thrombocytopenia (20.8%) were the most common adverse effects and these toxicities were deemed acceptable and manageable. In addition, a correlation was noted between elevated serum carcinoembryonic antigen (CEA) levels and decreased PFS and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incorporation of a 5-day continuous intravenous infusion of rh-endostatin into platinum-based doublet chemotherapy has demonstrated both safety and efficacy in the treatment of advanced NSCLC. Furthermore, the baseline serum levels of CEA may potentially function as a predictor for the efficacy of rh-endostatin when combined with chemotherapy in NSCLC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov<\/jats:title>\n                    <jats:p>NCT05574998.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10637-024-01439-x","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:37:57Z","timestamp":1714732677000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Xinyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiameng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Degan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"1","key":"1439_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. Cancer J Clin 70(1):7\u201330","journal-title":"Cancer J Clin"},{"issue":"10066","key":"1439_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet (London England) 389(10066):299\u2013311","journal-title":"Lancet (London England)"},{"issue":"1","key":"1439_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1186\/s12885-020-07690-8","volume":"20","author":"WM Brueckl","year":"2020","unstructured":"Brueckl WM, Ficker JH, Zeitler G (2020) Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 20(1):1185","journal-title":"BMC Cancer"},{"issue":"30","key":"1439_CR4","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N, Johnson D, Temin S et al (2017) Systemic therapy for Stage IV Non-small-cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncology: Official J Am Soc Clin Oncol 35(30):3484\u20133515","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"1439_CR5","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol 29(Suppl 4):iv192\u2013iv237","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"2","key":"1439_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92\u201398","journal-title":"N Engl J Med"},{"key":"1439_CR7","doi-asserted-by":"crossref","unstructured":"Gadgeel SM, Stevenson JP, Langer CJ et al (2018) Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. 125:273\u2013281 Lung cancer (Amsterdam, Netherlands)","DOI":"10.1016\/j.lungcan.2018.08.019"},{"issue":"3","key":"1439_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071\u20131121","journal-title":"Physiol Rev"},{"issue":"3","key":"1439_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","volume":"19","author":"DS Ettinger","year":"2021","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2021) NCCN guidelines Insights: Non-small Cell Lung Cancer, Version 2.2021. J Natl Compr Cancer Network: JNCCN 19(3):254\u2013266","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"24","key":"1439_CR10","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550","journal-title":"N Engl J Med"},{"issue":"19","key":"1439_CR11","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","volume":"33","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G et al (2015) BEYOND: a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin\/Paclitaxel plus Bevacizumab or placebo in Chinese patients with Advanced or Recurrent Nonsquamous Non-small-cell Lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol 33(19):2197\u20132204","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1439_CR12","doi-asserted-by":"crossref","unstructured":"Manzo A, Montanino A, Carillio G et al (2017) Angiogenesis inhibitors in NSCLC. Int J Mol Sci.;18(10)","DOI":"10.3390\/ijms18102021"},{"issue":"8","key":"1439_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncology: Official J Am Soc Clin Oncol 27(8):1227\u20131234","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"1439_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","volume":"361","author":"Y Ling","year":"2007","unstructured":"Ling Y, Yang Y, Lu N et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361(1):79\u201384","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1439_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/1759-7714.12050","volume":"4","author":"Y Sun","year":"2013","unstructured":"Sun Y, Wang JW, Liu YY et al (2013) Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac cancer 4(4):440\u2013448","journal-title":"Thorac cancer"},{"issue":"6","key":"1439_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/JTO.0b013e3182166b6b","volume":"6","author":"B Han","year":"2011","unstructured":"Han B, Xiu Q, Wang H et al (2011) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 6(6):1104\u20131109","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"28","key":"1439_CR17","doi-asserted-by":"publisher","first-page":"e4183","DOI":"10.1097\/MD.0000000000004183","volume":"95","author":"W Hu","year":"2016","unstructured":"Hu W, Fang J, Nie J et al (2016) Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine 95(28):e4183","journal-title":"Medicine"},{"issue":"7","key":"1439_CR18","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1002\/cam4.5526","volume":"12","author":"X Pu","year":"2023","unstructured":"Pu X, Wang Q, Liu L et al (2023) Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: a multicenter retrospective study. Cancer Med 12(7):7724\u20137733","journal-title":"Cancer Med"},{"issue":"Supplement","key":"1439_CR19","first-page":"S1148","volume":"14","author":"H Yang","year":"2018","unstructured":"Yang H, Sui Y, Guo X et al (2018) Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer. J Cancer Res Ther 14(Supplement):S1148\u2013s51","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"1439_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.12998\/wjcc.v10.i4.1164","volume":"10","author":"ZQ Qin","year":"2022","unstructured":"Qin ZQ, Yang SF, Chen Y et al (2022) Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. World J Clin Cases 10(4):1164\u20131171","journal-title":"World J Clin Cases"},{"issue":"9","key":"1439_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987\u2013989","journal-title":"Nat Med"},{"issue":"1","key":"1439_CR22","first-page":"79","volume":"17","author":"L He","year":"2018","unstructured":"He L, Zhao C, Li Y et al (2018) Antiangiogenic effects of recombinant human endostatin in lung cancers. Mol Med Rep 17(1):79\u201386","journal-title":"Mol Med Rep"},{"key":"1439_CR23","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (1990) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 2009;45(2):228\u2013\u200947","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"5","key":"1439_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","volume":"25","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Nakagawa K (2020) Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 25(5):818\u2013830","journal-title":"Int J Clin Oncol"},{"key":"1439_CR25","doi-asserted-by":"crossref","unstructured":"Hirabayashi T, Sonehara K, Ozawa R et al (2024) Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients With Advanced NSCLC Treated With a Combination Therapy of Anti-PD-1\/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study. Oncology","DOI":"10.1159\/000536120"},{"issue":"24","key":"1439_CR26","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"issue":"7","key":"1439_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/1759-7714.13106","volume":"10","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Nie L, Liu Y et al (2019) Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer. Thorac cancer 10(7):1576\u20131580","journal-title":"Thorac cancer"},{"issue":"10","key":"1439_CR28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/annonc\/mdi318","volume":"16","author":"AH Hansma","year":"2005","unstructured":"Hansma AH, Broxterman HJ, van der Horst I et al (2005) Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Annals Oncology: Official J Eur Soc Med Oncol 16(10):1695\u20131701","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"1","key":"1439_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/JTO.0000000000000343","volume":"10","author":"S Lu","year":"2015","unstructured":"Lu S, Li L, Luo Y et al (2015) A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 10(1):206\u2013211","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ethier JL, Lee DS et al (2017) Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 53:120\u2013127","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1439_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40487-017-0055-1","volume":"6","author":"K Li","year":"2018","unstructured":"Li K, Shi M, Qin S (2018) Current status and study progress of recombinant human endostatin in Cancer Treatment. Oncol Therapy 6(1):21\u201343","journal-title":"Oncol Therapy"},{"issue":"8","key":"1439_CR32","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cas.12451","volume":"105","author":"GW Prager","year":"2014","unstructured":"Prager GW, Braemswig KH, Martel A et al (2014) Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci 105(8):996\u20131001","journal-title":"Cancer Sci"},{"key":"1439_CR33","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.2147\/OTT.S171566","volume":"11","author":"B Li","year":"2018","unstructured":"Li B, Li C, Guo M et al (2018) Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. OncoTargets Therapy 11:6287\u20136294","journal-title":"OncoTargets Therapy"},{"issue":"4","key":"1439_CR34","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.21873\/anticanres.14974","volume":"41","author":"M Svaton","year":"2021","unstructured":"Svaton M, Blazek J, Krakorova G et al (2021) Prognostic role for CYFRA 21\u2013\u20091 in patients with Advanced-stage NSCLC treated with Bevacizumab Plus Chemotherapy. Anticancer Res 41(4):2053\u20132058","journal-title":"Anticancer Res"},{"issue":"22","key":"1439_CR35","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1158\/0008-5472.CAN-13-0123","volume":"73","author":"KH Bramswig","year":"2013","unstructured":"Bramswig KH, Poettler M, Unseld M et al (2013) Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 73(22):6584\u20136596","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01439-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T07:11:28Z","timestamp":1718003488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01439-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3514919\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Institutional Review Committee of the First Affiliated Hospital of Shandong First Medical University. Approved No. of ethic committee: YXLL-KY-2020(073). Written informed consent is obtained from all participants. This Trial was registered on ClinicalTrials.gov, NCT05574998.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}